Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
4.620
-0.540 (-10.47%)
At close: Nov 5, 2026, 4:00 PM EST
4.630
+0.010 (0.22%)
After-hours: Nov 5, 2026, 5:33 PM EST
Kyverna Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
149
Market Cap
285.72M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 7.03M | 1.37M | 24.20% |
| Dec 31, 2021 | 5.66M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Enanta Pharmaceuticals | 65.26M |
| Orchestra BioMed Holdings | 31.98M |
| X4 Pharmaceuticals | 15.85M |
| Alector | 13.86M |
| Opus Genetics | 9.86M |
| ProKidney | 818.00K |
KYTX News
- 13 days ago - Kyverna Therapeutics highlights updated clinical data with Miv-cel - TheFly
- 13 days ago - Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026 - GlobeNewsWire
- 14 days ago - Did Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PRNewsWire
- 15 days ago - Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto - GlobeNewsWire
- 4 weeks ago - Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026 - GlobeNewsWire
- 6 weeks ago - Kyverna Therapeutics Transcript: Study update - Transcripts
- 6 weeks ago - Kyverna Therapeutics Press release: Study update - Filings
- 6 weeks ago - Kyverna Therapeutics Slides: Study update - Filings